Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04608318
Study type Interventional
Source German CLL Study Group
Contact
Status Active, not recruiting
Phase Phase 3
Start date March 1, 2021
Completion date March 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04515238 - Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL Phase 2
Completed NCT00406809 - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT03766763 - Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Phase 2
Active, not recruiting NCT04883749 - Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL Phase 2
Recruiting NCT03804372 - The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide Phase 2
Active, not recruiting NCT00788684 - Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Phase 1
Terminated NCT01518959 - The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Phase 3
Completed NCT03787264 - Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL Phase 2
Recruiting NCT03852407 - Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning Phase 2
Recruiting NCT05350826 - Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia N/A